Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined antibiotic medicine for inhibiting beta-lactamase

A lactamase and drug technology, applied in the field of compound preparations and beta-lactamase inhibitors, can solve the problems of decreased efficacy and drug resistance of cefminox

Inactive Publication Date: 2004-09-08
周宇
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The invention aims at the problem that the curative effect of cefminox is decreased due to the resistant bacteria producing β-lactamase, and provides an antibacterial combination drug for inhibiting β-lactamase
To protect cefminox from being destroyed by β-lactamase produced by bacteria, and enhance its curative effect, so as to solve the problem of bacterial resistance to cefminox

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined antibiotic medicine for inhibiting beta-lactamase

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Embodiment 1: Under aseptic and clean conditions, 10 kilograms of cefminox sodium (calculated by cefminol) and 1 kilogram of potassium clavulanate (calculated by active acid) are mixed, and the powder injection preparation process is operated to prepare this product. Invented 10,000 powder injections.

Embodiment 2

[0042] Embodiment 2: Under aseptic and clean conditions, 10 kilograms of cefminox sodium (calculated by cefminol) and 20 kilograms of clavulanic acid potassium (calculated by active acid) are mixed, and the powder injection preparation process is operated to prepare this product. Invented 10,000 powder injections.

Embodiment 3

[0043] Embodiment 3: under aseptic and clean conditions, 10 kilograms of cefminox sodium (calculated by cefminol) and 2 kilograms of potassium clavulanate (calculated by active acid) are mixed, and are operated by the preparation process of freeze-dried powder injection, Prepare 10000 powder injections of the present invention.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The combined antibiotic medicine for inhibiting beta-lactamase is prepared by combining Cefminox as one kind of the third generation of cephalosporin and beta-lactamase inhibitor in certain weight ratio. The Cefminox is in the form of its alkali metal salt or its free acid plus co-solvent; and the beta-lactamase inhibitor is Sulbactam, Clavulanic acid, tazobactam or their derivative, such as Sulperazon, tazobactam sodium, potassium Clavulanate, etc. The beta-lactamase inhibitor and Cefminox of the present invention have obvious synergistic antibiotic effect and this makes it possible to solve the increasing resistance of pathogenetic bacteria to Cefminox clinically.

Description

technical field [0001] The invention relates to an antibiotic compound drug for inhibiting β-lactamase produced by bacteria, specifically a compound preparation composed of a β-lactamase inhibitor and third-generation cephalosporin antibiotic-cefminox. Background technique [0002] Cephalosporin antibiotics have been widely used clinically, and have achieved therapeutic effects that are difficult to achieve with traditional antibiotics. However, due to the long-term and extensive clinical use of antibiotics, and even the abuse of antibiotics, bacteria have become increasingly resistant to antibiotics. For example, penicillin in β-lactams was particularly effective when used 200,000 units each time in clinical practice in the 1950s, but now it is difficult to achieve results when 800,000 units are used each time. Cephalosporins, which belong to the same β-lactam class, also have obvious bacterial resistance. Cefminox (Cefminox) is the third-generation cep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K31/546A61P31/04
Inventor 周宇
Owner 周宇
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products